Xspray Pharma AB is a Swedish pharmaceutical company with a high ESG risk rating score of 30.6. Specializing in developing advanced PKIs for cancer treatment using their innovative HyNap technology platform. With a mission to improve clinical outcomes for cancer patients, Xspray Pharma aims to enhance the effectiveness, safety, and overall patient experience of existing cancer treatments. Their product lineup includes Dasynoc and various other candidates like XS003 nilotinib, XS008 axitinib, and XS00Y, all in different stages of development.